The AK1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt AK1 in the human A-549 lung adenocarcinoma line. This product offers a heterogeneous loss-of-function model that avoids clonal selection, enabling population-level analysis of AK1-dependent phenotypes without single-cell artifacts.
A-549 cells are adherent epithelial cells derived from a 58-year-old Caucasian male with lung carcinoma, exhibiting alveolar type II pneumocyte features. This well-characterized line serves as a standard model for human lung adenocarcinoma and retains key metabolic and signaling pathways relevant to nucleotide metabolism and cancer cell survival.
AK1 encodes a cytosolic adenylate kinase that catalyzes the reaction ATP + AMP ? 2 ADP, maintaining adenylate energy charge and nucleotide balance. Its activity is regulated by the AMP/ATP ratio and transcription factors HIF1A, MYC, and TP53 under energy stress. Downstream effects include modulation of AMPK signaling, ATP synthesis, mitochondrial respiration, and nucleotide interconversion enzymes. AK1 interacts with AMPK, P2Y receptors, nucleotide transporters, and adenine nucleotide translocase, placing it at a central hub for energy sensing and metabolic adaptation. Disruption of AK1 therefore affects adenine nucleotide ratios and downstream survival pathways.
In A-549 lung adenocarcinoma cells, AK1 knockout impairs energy homeostasis, creating a model to study cancer cell responses to nucleotide imbalance and metabolic stress. The loss of AK1 function may sensitize cells to energy-depleting conditions and influence proliferative signals through altered AMPK activation and HIF1A/MYC-driven metabolic programs. This polyclonal knockout model also provides a relevant system for exploring pathologies associated with adenylate kinase deficiency, such as hemolytic anemia, in an epithelial context.
Typical applications include functional characterization of AK1 in cancer metabolism, investigation of energy stress responses, drug target validation, and disease modeling. Compatible assays range from Western blot and RT-qPCR for AK1 expression to ATP/ADP/AMP quantification, Seahorse metabolic flux analysis, and HPLC-based nucleotide pool measurements. The polyclonal knockout background supports robust population-level metabolic studies and compound screening. For additional information, please contact Ascent Research.
